Core Viewpoint - Silver诺医药's new veterinary drug clinical trial application for the treatment of pet diabetes has been accepted by the Ministry of Agriculture, leading to a significant stock price increase of up to 20%, reaching HKD 31 [1] Group 1: Clinical Trial and Product Development - The core product, Isupatide α, is aimed at treating diabetes in pets, with the first phase of clinical trials expected to commence in the first quarter of this year [1] - The board believes that developing diabetes medication for pets has vast potential due to increasing consumer willingness to spend on extending their pets' lifespans [1] Group 2: Strategic Business Development - The board views this research and development as aligned with the company's long-term business strategy, establishing a solid foundation for future entry into the pet pharmaceuticals market [1]

Group 1 - The core product, Isupreglutide α, for treating pet diabetes has received formal acceptance for clinical trial application by the Ministry of Agriculture and Rural Affairs of China [1] - The stock price of the company surged, reaching a peak increase of 20%, trading at HKD 31 during the session [1] - The company plans to commence Phase I clinical trials in the first quarter of this year [1] Group 2 - The board believes that developing diabetes medication for pets has significant prospects due to increasing consumer willingness to spend on extending pet lifespans [1] - The board considers this research aligns with the company's long-term business development strategy and will establish a solid foundation for entering the pet pharmaceuticals market [1]

Core Viewpoint - The company, Yinnuo Pharmaceutical-B, has seen a significant stock price increase following the announcement of its clinical trial application for a new veterinary drug aimed at treating diabetes in pets, indicating strong market interest and potential growth in the pet pharmaceutical sector [1] Group 1: Company Developments - Yinnuo Pharmaceutical-B's core product, Isupatide α, has had its clinical trial application for treating pet diabetes officially accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The company plans to commence Phase I clinical trials in the first quarter of 2026, reflecting a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant prospects, as pet owners are increasingly willing to invest in extending their pets' lifespans [1] Group 2: Regulatory Compliance and Research Progress - The company has adhered to all regulatory standards and requirements related to veterinary drug research and registration set by the Ministry of Agriculture [1] - Yinnuo Pharmaceutical-B has successfully completed relevant preclinical trials, showing positive results in efficacy and safety for Isupatide α in managing pet diabetes [1] - The positive outcomes from preclinical trials provide a solid basis for the subsequent clinical trials and registration applications for the drug [1]

Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isu-Paglutide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isu-Paglutide α, is intended for the treatment of diabetes in pets [1] - The company has successfully completed all preclinical trials and met the regulatory standards set by the Ministry of Agriculture and Rural Affairs [1] - Positive results regarding efficacy and safety from preclinical trials provide a reasonable basis for subsequent clinical trials and registration applications [1] Group 2: Market Potential - The board believes that developing diabetes medications for pets has significant market potential due to increasing consumer willingness to spend on extending the lifespan of pets [1] - This research aligns with the company's long-term business development strategy and will lay a solid foundation for entering the pet pharmaceuticals market [1]

Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isupatide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isupatide α, is intended for the treatment of diabetes in pets, indicating a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant potential due to increasing consumer willingness to spend on extending pet lifespans [1] Group 2: Regulatory Compliance - The company has complied with all relevant standards and regulatory requirements for veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has been achieved, demonstrating positive progress in efficacy and safety for Isupatide α in managing pet diabetes [1]

Core Viewpoint - Silver诺医药-B (02591.HK) has received formal acceptance from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its clinical trial application of its core product, Isu-Paglutide α, for the treatment of diabetes in pets, with Phase I trials expected to commence in the first quarter of 2026 [1] Group 1: Product Development - The company believes that the development of diabetes medication for pets has significant potential due to increasing consumer willingness to invest in extending the lifespan of their pets [1] - The board views this research and development as aligned with the company's long-term business development strategy, laying a solid foundation for future entry into the pet pharmaceuticals market [1] Group 2: Regulatory Compliance and Trial Progress - The company has complied with all standards and regulatory requirements related to veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has shown positive progress in terms of efficacy and safety for Isu-Paglutide α in managing pet diabetes, providing a reasonable basis for subsequent clinical trials and registration applications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 自願性公告 依蘇帕格魯肽α的新獸藥臨床試驗申請獲受理 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東（「股東」）及有意投資者提供有關本公司業務最 新進展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年2月4日，本公司核心產 品依蘇帕格魯肽α用於治療寵物糖尿病的新獸藥臨床試驗申請已獲中華人民共和 國農業農村部（「農業部」）正式受理。預計將於2026年第一季度開始I期臨床試驗。 董事會認為，研發寵物糖尿病藥物具有廣闊的前景。由於人們愈發願意接受並花 費金錢延長寵物的壽命，董事會認為，此類研發符合本集團的長期業務發展策 略，並將為本集團未來 ...